Literature DB >> 29730449

Resilience trajectories to full recovery in first-episode schizophrenia.

Anne-Kari Torgalsbøen1, Susie Fu2, Nikolai Czajkowski3.   

Abstract

BACKGROUND: Resilience is successful adaptation despite adversity. This personality trait has the potential to add new knowledge to how to achieve a successful outcome, but resilience has been understudied in schizophrenia. The objective of the present study is to investigate if there are significant differences in resilience development among fully recovered and non-recovered patients with first episode schizophrenia (FES).
METHODS: In the ongoing Oslo Schizophrenia Recovery Study spanning 10 years, 28 first-episode patients are interviewed and assessed yearly with comprehensive criteria of full recovery, a measure of social and role functioning and resilience, the Connor-Davidson Resilience Scale. The present study includes data from six follow-ups over four years. Working or studying, having symptoms that are stably mild or absent for two years or more, having contact with friends and/or dating, participating in leisure activities and living independently define full recovery.
RESULTS: At the four-year follow-up, 55% were sustained full/partly recovered. Ten percent of those fully recovered were no longer in treatment. Choosing the overall best linear mixed model, we found a significantly larger increase in resilience score among the fully recovered than among those not recovered.
CONCLUSIONS: Based on the theoretical rationale that resilience is activated differently in persons who experience adversity, the significant increase in resilience in the fully recovered group indicates that this psychological trait is present to a higher degree in fully recovered. These results highlight resilience as a factor associated with increased recovery in FES adding to the small literature on improvement among these patients and thus have important clinical implications.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Course; Functional outcome; Longitudinal; Medication free; Psychosis; Recovery

Mesh:

Year:  2018        PMID: 29730449     DOI: 10.1016/j.eurpsy.2018.04.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  6 in total

1.  Aggression, Alexithymia and Sense of Coherence in a Sample of Schizophrenic Outpatients.

Authors:  Argyro Pachi; Athanasios Tselebis; Ioannis Ilias; Effrosyni Tsomaka; Styliani Maria Papageorgiou; Spyros Baras; Evgenia Kavouria; Konstantinos Giotakis
Journal:  Healthcare (Basel)       Date:  2022-06-10

2.  The Time is Ripe for a Consensus Definition of Clinical Recovery in First-episode Psychosis: Suggestions Based on a 10-Year Follow-up Study.

Authors:  Gina Åsbø; Torill Ueland; Beathe Haatveit; Thomas Bjella; Camilla Bärthel Flaaten; Kristin Fjelnseth Wold; Line Widing; Magnus Johan Engen; Siv Hege Lyngstad; Erlend Gardsjord; Kristin Lie Romm; Ingrid Melle; Carmen Simonsen
Journal:  Schizophr Bull       Date:  2022-06-21       Impact factor: 7.348

3.  Development of salutogenic coping skills: experiences with daily challenges among young adults suffering from serious mental illness.

Authors:  Jan-Freddy Hovland; Bente O Skogvang; Ottar Ness; Eva Langeland
Journal:  Int J Qual Stud Health Well-being       Date:  2021-12

Review 4.  First-episode psychosis: How long does it last? A review of evolution and trajectory.

Authors:  Jyoti Prakash; K Chatterjee; K Srivastava; V S Chauhan
Journal:  Ind Psychiatry J       Date:  2021-07-20

Review 5.  Guidelines for Discontinuation of Antipsychotics in Patients Who Recover From First-Episode Schizophrenia Spectrum Disorders: Derived From the Aggregated Opinions of Asian Network of Early Psychosis Experts and Literature Review.

Authors: 
Journal:  Int J Neuropsychopharmacol       Date:  2022-09-28       Impact factor: 5.678

Review 6.  Is It Possible to Predict the Future in First-Episode Psychosis?

Authors:  Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.